76472-88-3

Usage

Uses

Used in Pharmaceutical Industry:
Morachalcone A is used as a therapeutic agent for its anti-inflammatory, anti-cancer, and anti-diabetic properties, offering potential treatment for a variety of diseases.
Used in Antioxidant Applications:
Morachalcone A is used as an antioxidant, providing protection against oxidative stress and contributing to overall health and well-being.
Used in Research and Development:
Morachalcone A is used as a subject of ongoing research to further explore its potential as a valuable therapeutic agent for various medical conditions and to develop novel drug delivery systems to enhance its efficacy and bioavailability.

Upstream product

• 850868-90-5 (2E)-3-[2',4'-bis(methoxymethoxy)phenyl]-1-(2-hydroxy-3-(3-methylbut-2-en-1-yl)-4-{[2-(trimethylsilyl)ethoxy]methoxy}phenyl)prop-2-en-1-one 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 13709-06-3 2,4-bis(methoxymethoxy)benzaldehyde 
• 95-01-2 2,4-Dihydroxybenzaldehyde 
• 850868-88-1 1-(2-hydroxy-4-{[2-(trimethylsilyl)ethoxy]methoxy}phenyl)ethanone 
• 358-72-5 dimethylallyl diphosphate 
• 25972-30-9 (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one 
• 850868-89-2 (2E)-3-[2',4'-bis(methoxymethoxy)phenyl]-1-(2-[(3-methylbut-2-en-1-yl)oxy]-4-{[2-(trimethylsilyl)ethoxy]methoxy}phenyl)prop-2-en-1-one 
• 850868-87-0 (E)-3-(2,4-Bis-methoxymethoxy-phenyl)-1-[2-hydroxy-4-(2-trimethylsilanyl-ethoxymethoxy)-phenyl]-propenone 

Relevant academic research and scientific papers

Molecular Characterization and Phylogenetic Analysis of Two Novel Regio-specific Flavonoid Prenyltransferases from Morus alba and Cudrania tricuspidata

Prenylated flavonoids are attractive specialized metabolites with a wide range of biological activities and are distributed in several plant families. The prenylation catalyzed by prenyltransferases represents a Friedel-Crafts alkylation of the flavonoid skeleton in the biosynthesis of natural prenylated flavonoids and contributes to the structural diversity and biological activities of these compounds. To date, all identified plant flavonoid prenyltransferases (FPTs) have been identified in Leguminosae. In the present study two new FPTs, Morus alba isoliquiritigenin 3′-dimethylallyltransferase (MaIDT) and Cudrania tricuspidata isoliquiritigenin 3′-dimethylallyltransferase (CtIDT), were identified from moraceous plants M. alba and C. tricuspidata, respectively. MaIDT and CtIDT shared low levels of homology with the leguminous FPTs. MaIDT and CtIDT are predicted to be membrane-bound proteins with predicted transit peptides, seven transmembrane regions, and conserved functional domains that are similar to other homogentisate prenyltransferases. Recombinant MaIDT and CtIDT were able to regioselectively introduce dimethylallyl diphosphate into the A ring of three flavonoids with different skeleton types (chalcones, isoflavones, and flavones). Phylogenetic analysis revealed thatMaIDT and CtIDT are distantly related to their homologs in Leguminosae, which suggests that FPTs in Moraceae and Leguminosae might have evolved independently. MaIDT and CtIDT represent the first two non-Leguminosae FPTs to be identified in plants and could thus lead to the identification of additional evolutionarily varied FPTs in other non-Leguminosae plants and could elucidate the biosyntheses of prenylated flavonoids in various plants. Furthermore, MaIDT and CtIDT might be used for regiospecific prenylation of flavonoids to produce bioactive compounds for potential therapeutic applications due to their high efficiency and catalytic promiscuity.

The synthetic preparation of naturally-occurring aromatase inhibitors, morachalcone A, isogemichalcone B, and isogemichalcone C

A convergent synthesis applicable to the preparation of oxidized prenylchalcones is reported that relies on key Claisen-Schmidt, Mitsunobu, and vinyl/benzyl Stille coupling operations. The synthetic strategy was applied towards the preparation of the natu

A short synthesis of morachalcone A

Advanced C-prenylated intermediates for three aromatase inhibitors, including morachalcone A, can be synthesized through a Claisen-Schmidt condensation followed by Florisil-catalyzed [1,3]-sigmatropic rearrangement of a prenyl phenyl ether.

Aromatase inhibitors from Broussonetia papyrifera

A composition and method of cancer treatment is disclosed. The composition and method utilized the extract of B. papyrifera, or compounds included therein having aromatase inhibition properties, as active cancer chemopreventative and treating agents in mammals, including humans.